Dr. Tolaney on Sequencing Strategies in Metastatic HER2+ Breast Cancer
Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast CancerПодробнее
Dr. Tolaney on Sequencing Questions in Breast CancerПодробнее
Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment StrategiesПодробнее
Cancer and Us gets a port for breast cancer HER2 Positive Chemo treatmentПодробнее
Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast CancerПодробнее
Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast CancerПодробнее
Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast CancerПодробнее
Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast CancerПодробнее
Dr. Tolaney on Activity With Abemaciclib in Patients With HR+/HER2– Breast CancerПодробнее
Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast CancerПодробнее
Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast ConferenceПодробнее
Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Breast CancerПодробнее
Dr. Anders on Sequencing Strategies in the Setting of HER2+ Brain MetastasisПодробнее
Dr. Tolaney on the ATEMPT Trial for HER2+ Breast CancerПодробнее
Dr. Tolaney Discusses Pertuzumab in HER2+ Breast CancerПодробнее
Treatment strategies for HER2+ metastatic breast cancerПодробнее
Sequencing novel HER2-targeted therapies in metastatic breast cancerПодробнее
Dr Sara M. Tolaney: Standard of Care, Novel Approaches For Treatment of HER2-Positive Breast CancerПодробнее
Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast CancerПодробнее
